(+/-) 3-(6-Phenyl-3-pyridazinyl)-9-methyl-3,9-diazabicyclo-[4.2.1]-nonane | 387869-60-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (+/-) 3-(6-Phenyl-3-pyridazinyl)-9-methyl-3,9-diazabicyclo-[4.2.1]-nonane
• 英文别名: 9-Methyl-3-(6-phenylpyridazin-3-yl)-3,9-diazabicyclo[4.2.1]nonane
• CAS: 387869-60-5
• 化学式: C₁₈H₂₂N₄
• 分子量: 294.399
• InChiKey: QRPOTLDUMNHHTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Aryl and heteroaryl diazabicycloalkanes, their preparation and use
  申请人：——

  公开号：US20030176416A1

  公开（公告）日：2003-09-18

  The present invention relates to novel aryl and heteroaryl diazabicycloalkane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型芳基和杂环基二氮杂双环庚烷衍生物，发现它们是乙酰胆碱受体的胆碱能配体，并且是单胺受体和转运体的调节剂。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩有关的疾病或障碍，内分泌疾病或障碍，神经退行性疾病或障碍，炎症有关的疾病或障碍，疼痛以及由于滥用化学物质终止而引起的戒断症状等多种疾病或障碍具有用处。
• ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE
  申请人：NEUROSEARCH A/S

  公开号：EP1301514A1

  公开（公告）日：2003-04-16
• US7060699B2
  申请人：——

  公开号：US7060699B2

  公开（公告）日：2006-06-13
• [EN] ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE<br/>[FR] DIAZABICYCLOALKANES ARYLE ET HETEROARYLE, ELABORATION ET UTILISATION
  申请人：NEUROSEARCH AS

  公开号：WO2002002564A1

  公开（公告）日：2002-01-10

  The present invention relates to novel aryl and heteroaryl diazabicycloalkane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.